CD19 and myeloid sarcoma: First, we analyzed percentages of total CD19+ B cells in NMOSD and MS, which showed no significant differences compared to HC (NMOSD n = 12, median: 6.3, and range: 1-20.7; MS n = 15, median: 7.3, and range: 0.5-32.7; and HC n = 6, median: 7.3, and range: 3.8-12.7).